

AMENDMENT TO RULES
COMMITTEE PRINT 118-36
OFFERED BY MR. WENSTRUP OF OHIO

At the end of subtitle B of title VII, insert the following new section:

1 **SEC. 8__ . REQUIREMENT TO PROCURE DOMESTICALLY**
2 **PRODUCED GENERIC DRUGS.**

3 (a) IN GENERAL.—Subchapter II of chapter 385 of
4 title 10, United States Code, is amended by adding at the
5 end the following new section:

6 **“§ 4865. Procurement of domestically produced ge-**
7 **neric drugs**

8 “(a) REQUIREMENT.—Subject to subsection (b), the
9 Secretary of Defense may not enter into a contract for
10 the procurement of generic drugs for members of the uni-
11 formed services and dependents of such members unless
12 the generic drugs—

13 “(1) are manufactured in the United States;

14 and

15 “(2) use active pharmaceutical ingredients and
16 key starting materials sourced from—

17 “(A) the United States; or

1 “(B) a foreign country or instrumentality
2 designated under subsection (b) of section 301
3 of the Trade Agreements Act of 1979 (19
4 U.S.C. 2511) for purposes of the waiver author-
5 ity under subsection (a) of that section.

6 “(b) EXCEPTION.—(1) The Secretary may waive the
7 requirement under subsection (a) if the Secretary deter-
8 mines that satisfactory quality and sufficient quantity of
9 a generic drug described in such subsection cannot be pro-
10 cured as and when needed at United States market prices.

11 “(2) The Secretary of Defense shall submit to the
12 congressional defense committees a written notice of each
13 waiver under this subsection not later than 15 days after
14 granting such waiver.

15 “(c) DISCLOSURE REQUIREMENT.—The Secretary
16 shall require an offeror for a contract described in sub-
17 section (a) to disclose the country of origin of the active
18 pharmaceutical ingredients and key starting materials for
19 the generic drugs that are the subject of such contract.

20 “(d) DEFINITIONS.—In this section:

21 “(1) The term ‘active pharmaceutical ingre-
22 dient’ has the meaning given such term in section
23 744A(2) of the Federal Food, Drug, and Cosmetic
24 Act (21 U.S.C. 379j-41).

25 “(2) The term ‘generic drug’—

1 “(A) means a drug—

2 “(i) approved under subsection (b)(2)
3 or (j) of section 505 of the Federal Food,
4 Drug, and Cosmetic Act (21 U.S.C. 355);
5 or

6 “(ii) licensed under section 351(k) of
7 the Public Health Service Act (42 U.S.C.
8 262(k)); and

9 “(B) included on the joint uniform for-
10 mulary established under section 715 of the
11 National Defense Authorization Act for Fiscal
12 Year 2016 (10 U.S.C. 1074g note).

13 “(3) The term ‘key starting material’ means a
14 raw material, an intermediate, or an active pharma-
15 ceutical ingredient that is used in the production of
16 an active pharmaceutical ingredient and that is in-
17 corporated as a significant structural fragment into
18 the structure of the active pharmaceutical ingre-
19 dient.”.

20 (b) APPLICABILITY.—This section and the amend-
21 ments made by this section shall apply with respect to con-
22 tracts entered into on or after the date of the enactment
23 of this section.

